The Lactate test, as part of the epoc Blood Analysis System, is intended for use by trained medical professionals as an in vitro diagnostic device for the quantitative testing of samples of heparinized or un-anticoagulated arterial, venous or capillary whole blood in the laboratory or at the point of care in hospitals, nursing homes or other clinical care institutions.

Lactate measurements from the epoc Blood Analysis System are used to evaluate the acid-base status and are used in the diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood).

Device Description

The epoc Lactate Test is being added as an additional sensor to the existing single use test card that is used with the epoc Blood Analysis System. This test card is inserted into the epoc Reader and all analytical steps are performed automatically. Patient and user information may be entered into the mobile computing device (epoc Host) during the automated analysis cycle.

The epoc Blood Analysis System is an in vitro analytical system comprising a network of one or more epoc Readers designed to be used at the point of care (POC). The readers accept an epoc single use test card containing a group of sensors that perform diagnostic testing on whole blood. The blood test results are transmitted wirelessly to an epoc Host, which displays and stores the test results.

AI/ML Overview

Here's a summary of the acceptance criteria and study information for the epoc Lactate Test, based on the provided document:

1. Table of Acceptance Criteria and Reported Device Performance (Lactate only)

Acceptance Criteria Category	Specific Metric (Lactate)	Acceptance Criteria (Implicit)	Reported Device Performance (Lactate)
Precision (Aqueous Controls)	Within-Device CV%	Not explicitly stated but expected to be low for clinical accuracy.	L1: 4.9% (WD), 6.3% (Total); L3: 3.1% (WD), 4.7% (Total)
Precision (Blood Samples - Site 1)	%CV	Not explicitly stated.	WB L1: 6.0% (Phlebotomist 1), 3.3% (Phlebotomist 2)
Precision (Aqueous Controls - Site 1)	%CV	Not explicitly stated.	L3: 3.3% (RN 1), 2.9% (Anesthesia Tech); L2: 1.8% (RN 2), 2.8% (Resp Therapist)
Linearity/Reportable Range	Test Range (mM)	0.3 - 20 mmol/L (as specified in technology comparison)	0.001 - 20.1 mM (appears to be "test range" based on the table, indicating it covers the specified range)
Traceability	To NIST standards	Device calibrated and QC materials traceable to NIST.	Explicitly states: "epoc System is calibrated is against methods traceable to NIST standards." and "Calibration verification uses commercially available calibration verification fluids whose concentration values are traceable to NIST standards."
Detection Limit	Statistically discernable from Limit of Blank	Test's low end of reportable range >= Limit of Detection	Low end of reportable range (0.30 mM) is >= Limit of detection and statistically discernable from Limit of Blank (0.21 mM).
Analytical Specificity (Interference Bias)	Unacceptable bias defined as >5% significant error.	Max 5% significant error.	Several interfering substances listed with specific bias values; most found to be "insignificant" at tested levels.
Method Comparison (vs. Predicate)	R²	Generally >0.95 for good correlation.	0.9711 (overall), 0.9769 (venous), 0.9829 (arterial), 0.9653 (capillary)
Method Comparison (vs. Predicate)	Slope	Ideally close to 1.	0.967 (overall)
Method Comparison (vs. Predicate)	Intercept	Ideally close to 0.	0.132 (overall)
Method Comparison (vs. Predicate) - Bias	Average Bias for decision levels	Expected to be small, with narrow 95% CI.	At 2.2mM: 0.061 (all) with 95% CI ± 0.119; At 5.0mM: -0.031 (all) with 95% CI ± 0.084
Effect of Anticoagulant (vs. Predicate)	R²	Generally >0.95 for good correlation.	0.9916
Effect of Anticoagulant (vs. Predicate)	Slope	Ideally close to 1.	1.036
Effect of Anticoagulant (vs. Predicate)	Intercept	Ideally close to 0.	-0.045

2. Sample Size and Data Provenance

Test Set for Method Comparison:
- Sample Size: 373 patient samples for overall method comparison; broken down into 126 venous, 73 arterial, 174 capillary samples for matrix effects.
- Data Provenance: Field trials at several hospitals on "patient samples of whole blood at various locations." This indicates prospective, real-world data from multiple sites (likely within North America given the FDA submission).
Test Set for Blood Precision:
- Sample Size: 15 samples per user at Site 1, and unspecified number at Site 2 (likely similar).
- Data Provenance: Field trials at two (2) hospitals on "volunteer samples of whole blood by potential end users." This indicates prospective, real-world data from multiple sites.
Test Set for Aqueous Precision:
- Sample Size: 15 samples per user per QC level at Site 1, and unspecified number at Site 2 (likely similar).
- Data Provenance: Field trials at two (2) hospitals on commercially available control fluids by potential end users.
Test Set for Anticoagulant Effect:
- Sample Size: 60 samples (43 from hospital POC sites, 17 from in-house studies).
- Data Provenance: Patient samples from hospital POC sites and in-house studies.

3. Number of Experts and their Qualifications (for Test Set Ground Truth)

The document describes the predicate device as the "gold standard" for comparison. The ground truth for the method comparison studies was established by the predicate device (i-Stat™ Lactate Test using i-Stat™ Model 300 Portable Clinical Analyzer).
No specific number of human experts or their qualifications for establishing ground truth are mentioned, as the comparison is against another established device. However, the predicate device itself would have undergone its own validation with expert input.

4. Adjudication Method

Given that the ground truth is established by a predicate analytical device, there is no human adjudication method (like 2+1 or 3+1) described or applicable in this context. The comparison is quantitative against readings from the predicate device.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

A formal MRMC comparative effectiveness study, as typically performed for diagnostic imaging devices involving human readers, was not conducted or described.
The studies involved different "users" (phlebotomists, RNs, Anesthesia Techs, Resp Therapists) performing tests, which is a form of multi-reader study, but it's focused on device precision/reproducibility across different operators rather than assessing AI assistance for human diagnostic performance. Therefore, there is no effect size reported for human readers improving with/without AI assistance.

6. Standalone Performance Study

Yes, a standalone performance study was done. The entire document describes the standalone performance of the epoc Lactate Test (algorithm and device combined) against a predicate device and established analytical standards. The reported device performance metrics in the tables (precision, linearity, method comparison slope, intercept, R², bias) are all measures of the device's standalone performance. There is no human-in-the-loop component for result interpretation.

7. Type of Ground Truth Used

The primary ground truth for the clinical and non-clinical studies is:
- Readings from a legally marketed predicate device (i-Stat™ Lactate Test using i-Stat™ Model 300 Portable Clinical Analyzer) for method comparison studies.
- NIST traceable standards for calibration, quality control, and linearity studies.
- Pooled human serum and blood samples (spiked with known interferents or aged to increase lactate) for analytical specificity and blood precision studies.

8. Sample Size for the Training Set

The document does not explicitly state the sample size for the training set for the epoc Lactate Test development. This type of submission (510(k) for an IVD) typically focuses on validation data rather than internal development/training data for the algorithm.

9. How the Ground Truth for the Training Set was Established

As the training set size is not disclosed, the method for establishing its ground truth is also not explicitly described in this document. However, given the nature of the device (a quantitative sensor measurement system), the training/development likely involved:
- Controlled reference materials with known lactate concentrations.
- Comparison to reference laboratory methods known to be accurate and traceable to NIST standards.

Summary

{0}------------------------------------------------

K073257

JUN - 9-2010

ероса

2060 Walkley Road Ottawa Ontario, Canada K1G 3P5

510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: k-093297.

Summary Prepared: June 07, 2010

Submitted by:	Epocal Inc.2060 Walkley Road, Ottawa, Ontario, Canada K1G 3P5Telephone: (613) 738-6192Fax: (613) 738-6195
Contact:	Roy Layer

Director of Quality Assurance and Regulatory Affairs.

5.1 Identification of the Device

Device Name:	Acid, Lactic, Enzymatic Method
Proprietary / Trade Name:	epoc Lactate Test
Common Name:	Lactate acid test system
Classification Name:	Acid, Lactic, Enzymatic Method
Device Classification:	I (Class II with limitation of exemption)
Regulation Number:	862.1450
Panel:	Clinical Chemistry
Product Code:	KHP

Identification of the Predicate Device 5.2

i-Stat™ Lactate Test using i-Stat™ Model 300 Portable Clinical Analyzer

Description of the New Device 5.3

{1}------------------------------------------------

The epoc System is intended for use by trained medical professionals as an in vitro diagnostic device for the quantitative testing of samples of whole blood.

The test card panel configuration currently includes sensors for Sodium Na, Potassium K, Ionized Calcium iCa, pH, pCO2, pO2, Glucose and Hematocrit Hct. This submission adds Lactate (Lact) to this list of approved tests.

To perform a blood test, a new test card is inserted into a card reader's card slot with white label face down. When fully inserted, the test card is automatically engaged in the reader.

The card insertion process:

Brings the cards sensor module into contact with the reader's electrical contact . array;
Brings the card's measurement region, which is the fluidic channel above the . sensor array, into thermal contact with the reader's heater assembly for heating the measurement region to 37℃;
Actuates the opening of the fluidic valve in the card and causes delivery of . calibrator fluid from the reservoir to the measurement region.

After calibration, and upon a prompt by the reader (LED visual and audio beep), the user introduces a blood sample for measurement through the blood sample port to the card's measurement region. When sensors are contacted by the blood sample they generate electrical signals proportional to analyte concentrations in the blood sample, which are transmitted wirelessly by the Reader to the epoc Host displays and stores the blood test results.

Changes to the epoc Blood Analysis System required to introduce the Lactate test include:

Developing a new Lactate sensor and adding it to the existing epoc test card, . which was already designed to accommodate additional sensors;
Modifications to the existing EpocHost software application to accommodate the . new test:
. Labeling changes including indications for use for the Lactate test.

Comparison of Technological Characteristics To Predicate 5.4 Device

510(k) #	epoc Blood Analysis System	i-STAT Model 300	Same / Different
Item	Device	Predicate
Intended use	The Lactate test as part of epoc BloodAnalysis System is intended for use bytrained medical professionals as an invitro diagnostic device for thequantitative testing of samples ofheparinized or un-anticoagulatedarterial, venous or capillary wholeblood using the BGEM (Blood GasElectrolyte and Metabolytes) test cardpanels.	The i-STAT Model 300 Portable ClinicalAnalyzer is intended to be used bytrained medical professionals for usewith i-STAT test cartridges. i-STATcartridges comprise a variety ofclinical chemistry tests and testpanels.	same
Where used	hospital	hospital	same

{2}------------------------------------------------

Measuredparameters	pH, pCO2, pO2, Na, K, iCa, Hct, Gluc, Lact		pH, pCO2, pO2, Na, K, iCa, Hct, Gluc, Lact			same
Calculatedparameters	TCO2, HCO3, BE, SO2, Hgb		TCO2, HCO3, BE, SO2, Hgb			same
Sample type	Venous, arterial and capillary whole blood		Venous, arterial and capillary whole blood			same
Reportableranges	pH	6.5 - 8.0pH units	pH	6.5 - 8.2pH units	different
	pCO2	5 - 250mm Hg	pCO2	5 - 130mm Hg	different
	pO2	5 - 750mm Hg	pO2	5 - 800mm Hg	same
	Na	85 - 180mmol/L	Na	100 - 180mmol/L	different
	K	1.5 - 12mmol/L	K	2.0 - 9.0mmol/L	different
	iCa	0.25 - 4mmol/L	iCa	0.25 - 2.5mmol/L	different
	Hct	10 - 75%PCV	Hct	10 - 75%PCV	same
	Gluc	20 - 700mg/dL	Gluc	20 - 700mg/dL	same
	Lact	0.3 - 20mmol/L	Lact	0.3 - 20mmol/L	same
	TCO2	1 - 85mmol/L	TCO2	5 - 50mmol/L	different
	HCO3	1 - 85mmol/L	HCO3	1 - 85mmol/L	same
	BEecf	-30 - +30mmol/L	BEecf	-30 - +30mmol/L	same
	BEB	-30 - +30mmol/L	BEB	-30 - +30mmol/L	same
	SO2	0 - 100%	SO2	0 - 100%	same
	Hb	3.3 - 25g/dL	Hb	3 - 26g/dL	same
Samplevolume	Non-volumetric over 95 µL		100µL			same
Test card	Unit-use card withon-board calibrator in sealedreservoiran electrochemical multi-sensor arrayport for sample introductionfluid waste chamber		Unit-use cartridge withon-board calibrator in sealedreservoiran electrochemical multi-sensor arrayport for sample introductionfluid waste chamber			same
Test cardstorage	Room temperature until expiry date		Fridge storage until expiry dateincluding max 2 weeks at room temperature			different
Sensor array	A laminated foil sensor module		A micro-fabricated chip-set			different
Tests/sensorcomponents	pH - PVC ion selective electrodepCO2 - QH modified Severinghaus typepO2 - membrane coated gold cathodeNa - PVC ion selective electrodeK - PVC ion selective electrodeiCa - PVC ion selective electrodeGlu - glucose oxidase basedamperometric peroxide detectionLact - lactate oxidase basedamperometric peroxide detectionHct - conductivity, gold electrodes		pH - PVC ion selective electrodepCO2 - QH modified Severinghaus typepO2 - membrane coated gold cathodeNa - PVC ion selective electrodeK - PVC ion selective electrodeiCa - PVC ion selective electrodeGlu - glucose oxidase basedamperometric peroxide detectionLact - lactate oxidase basedamperometric peroxide detectionHct - conductivity, gold electrodes			same
Analyzercomponents	Two housings;1 - The reader comprisingOrifice for test card introductionelectrical connector to cardheater for 37°C operationmechanical card engagement device for- making electrical contact to card's sensors- for rupture of calibrator reservoir- moving calibrator to sensors- engaging heaters with cardop-amp sensor signal detectorsiQC monitoring devices		A single housing comprisingOrifice for test card introductionelectrical connector to cardheater for 37°C operationmechanical card engagement device for- making electrical contact to card's sensors- for rupture of calibrator reservoir- moving calibrator to sensors- engaging heaters with cardop-amp sensor signal detectorsiQC monitoring devices			different

{3}------------------------------------------------

	MUXA/DBluetooth stack for wirelesstransmission of digitized rawsensor signals to computingdevicebar code scanner for acquiringcard infointernal electronic reader self-testcircuit2 - The computing device comprisinga PDAmicroprocessor	MUXA/Dwire transmission of digitized rawsensor signals to computingsubsystem in same housingn/ainternal and external electronicreader self-test circuitmicroprocessormemory	samesamedifferentdifferentdifferentsamesame
	memorycolor LCD display	monochrome LCD display	different
	keyboard	keyboard	same
	i/o for communicating test results	i/o for communicating test results	same
	to other devices	to other devices
	software to control the test andcalculate analytical values fromraw sensor signals	software to control the test andcalculate analytical values fromraw sensor signals	same
	battery operated withrechargeable batteries via plug inplug-in power supply	battery operated withrechargeable batteries viaexternal power supply indownloader cradle	same
Measurementtemperature	37°C	37°C	same
	Measurement Calibrate test card-introduce sample-	Introduce sample-calibrate test	different
sequence	measure	cartridge-measure
Measurementtime	35sec from sample introduction	200 sec from sample introduction	different
Error	iQC system to detect user errors	iQC system to detect user errors	same
detection	iQC system for reader self-check	iQC system for reader self-check	same
	iQC system to detect card non-	iQC system to detect card non-	same
	conformance	conformance

Figure 5.1 - Table - Comparing epoc Device Performance Characteristics With Predicate Device

The epoc System has the same intended use and utilizes the same test methodologies as the predicate device. Most of the system components are very similar to the predicate device. Differences between the epoc device and the predicate device have no significant effect on the safety or effectiveness of the system.

{4}------------------------------------------------

Summary of Non-Clinical Test Performance in Support of 5.5 Substantial Equivalence

5.5.1 Aqueous precision

Experiments were performed in-house to demonstrate the precision of the epoc test methods. The table below shows the results of a twenty day precision study using performed on 4 lots using aqueous controls at two levels L1 and L3 for the blood gases, electrolytes and metabolytes.

Lactate	All
mM	L1	L3
N	320	320
Mean	7.99	0.94
SWD	0.39	0.03
SDD	0.32	0.03
ST	0.51	0.04
WD CV%	4.9%	3.1%
Total CV%	6.3%	4.7%

Figure 5.2 - Table - 20 Day Precision Study Data

Linearity/Reportable Range 5.5.2

This study was performed in-house using blood samples as per CLSI EP6-A recommendations for evaluation of linearity. A total of nine blood samples were prepared starting with two pools of blood, which were evaluated versus an in-house standard method with traceability to NIST standards. Regression analysis was performed as per CLSI EP6-A. The summary is given in the table in Figure 5.3.

	" est Range "Slope		C
CmMl20.1ﺗﺄﺳﻴﺴﺎﺕ ﺳﻨﺔ 1999 ﻓﻲ ﺇﺳﺒﺎﻧﻴﺎ ﻓﻲ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤ	.001	0.77	n qaqaﻟﻠﺴﻠﺔ ﺍﻟﻤﺴﺎﺣﺔ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ

Figure 5.3 – Table - In House Whole Blood Linearity

5.5.3 Traceability

The epoc System is calibrated is against methods traceable to NIST standards.

The epoc System's test card comprises an on-board calibration material, prepared gravimetrically and assayed on reference systems calibrated with traceability to NIST standards.

Calibration verification uses commercially available calibration verification fluids whose concentration values are traceable to NIST standards.

Quality control materials are commercially available fluids with concentrations traceable to NIST standards.

5.5.4 Detection Limit

This study was performed in-house as per CLSI EP6-A recommendations for evaluation limits of detection and quantification. The low end of the reportable range for the EPOC lactate test (0.30 mM) is greater than or equal to the limit of detection and is statistically discernable from the limit of blank ( 0.21 mM).

{5}------------------------------------------------

Analytical Specificity 5.5.5

Interference testing4 was performed in-house on the epoc lactate sensor. In each of these tests a pooled human serum was aliguoted into two samples. The test sample was spiked by addition of interferent, while the control sample was spiked by the addition of the solvent of the interferent. The lactate bias between the mean of six replicates on both the control sample and the test sample with added interferent was calculated.

Unacceptable interference bias was defined as producing a significant error more than 5% of the time.

Significant interfering substances are itemized below:

· Acetaminophen will have no significant effect up to 0.81 mM after which it will increase the lactate reading up to 306 µM/mM Tylenol. Because the therapeutic upper limit for acetaminophen is 0.20 mM, interfering levels of acetaminophen should only be encountered in overdose situations
· Iodide will decrease the lactate reading up to -1.2mM/mM of Iodide up to an Iodide concentration of 0.67 mM. Above 0.67 mM Iodide the decrease will be -1.2mM.
Bromide will have no significant effect up to 25.4 mM after which it will decrease the lactate reading up to 14.6 µM/mM Bromide.
· Thiocyanate will have no significant effect up to 2.7 mM after which it will decrease the lactate reading by up to 96.6 µM/mM thiocyanate.
N-Acetylcysteine will have no significant effect up to 3.7 mM after which it will decrease the lactate reading by up to 96.3 uM/mM N-Acetylcysteine.

Ethylene glycol ingestion and metabolism has been shown to produce falsely elevated lactate measurements*. Ethylene glycol plus three metabolism products -Glycolic Acid, Glyoxylic Acid and Oxalic Acid - were tested for interference. Ethylene Glycol and Oxalic Acid do not interfere significantly.

· Glycolic Acid will have no significant effect up to 0.87 mM after which it will increase the lactate reading up to 142 µM/mM glycolic acid.
Glyoxylic Acid will have no significant effect up to 0.85 mM after which it will increase the lactate reading up to 373 uM/mM qlyoxylic acid.

CMAJ, April 10, 2007, 176(8), p.1097 "Falsely elevated point-of-care lactate measurement after ingestion of ethylene glycol"

The following levels of exogenous interferences were tested and found to be insignificant: 1.66mM (25mg/dL) acetaminophen, 630µmol/L (12.5mg/dL) Na ascorbate. 20mmol/L (588 mg/dL) citrate. 100 umol/L (~2mg/dL) L-dopa, 9mmol/L (263mg/dL) EDTA, 4.84mmol/L (30mg/dL) ethylene glycol, 105 µmmol/L (0.441mg/dL) Na fluoride, 71 µmol/L Methyldopa, 2.55mmol/L oxidized glutathione, 2.55mmol/L reduced glutathione, 132 umol/L (1.0mg/dL) hydroxyurea, 292µmol/L (4mg/dL) isoniazide (nydrazid), 81 µmol/L (1.5 mg/dL) K Oxalate, 0.037 mmol/L (1.2 mg/dL) Quinidine.

The following levels of endogenous interferences were tested and found to be insignificant: +342µmol/L (+29.0mg/dL) bilirubin conjugated, +342 (+20.1mg/dL) bilirubin unconjuqated, +13mmol/L (+503.1mg/dL) cholesterol, +1500umol/L (+18mg/dL) L-cysteine, +0.8% lipids, pH (+0.4, -0.4), 3% to 10% total protein, 1.4 mM (+ 23.5 mg/dL) Uric Acid.

{6}------------------------------------------------

Low hematocrit did not interfere down to a level of 21 % hematocrit and high hematocrit did not interfere up to a level of 61 % hematocrit. Triglycerides did not show significant interference up to a level of 37 mM (1430 ma/dL).

Summary of Clinical Tests Submitted in Support of 5.6 Substantial Equivalence

5.6.1 Method comparison with Predicate Device

The method comparison studies were performed in field trials at several hospitals on patient samples of whole blood at various locations. Patient specimens were venous, arterial and capillary. The method comparison was against the predicate device.

epoc Lactate vs. i-STAT
N	373
Sxx	0.215
Syy	0.530
intercept	0.132
slope	0.967
Syx	0.948
X min	0.48
X max	19.95
R²	0.9711

Figure 5.6 - Table of Method Comparison Summary against Predicate Device

5.6.2 Blood Precision

Blood precision studies were performed in field trials at two (2) hospitals on volunteer samples of whole blood by potential end users. One (1) sample was obtained and tested fresh (WB L2). Another sample was obtained and held for several hours to increase lactate concentration (WB L1). This sample was introduced via epoc Care-Fill Capillary Tubes.

Site 1

User	QC Level	N	Avg	SD	%CV	lot
Phlebotomist 1	WB L1	15	10.24	0.62	6.0%	09231/09230
Phlebotomist 2	WB L1	15	10.27	0.34	3.3%	09231/09230

Figure 5.7 - Table - Blood Precision Study Summary (Site 1)

Site 2

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ER ESSEE INVESTIENT FORMERCar				4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-A MINILES EN LANDINGER MIRANIL SEMENTE MILLING MALE(A MIN R LEN & COMMENT IN OR LE	-----------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	1	11. And A CHINESS - A Charles An An-	1	പ്രാമം.
Station of Arms Andrew Associated on Area aAnd All Andיחמם/S		A-4-60-100		------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	10727CAR AN ANNUAL CONNECT CHARACT CHANAL

Figure 5.8 - Table - Blood Precision Study Summary (Site 2) - Sample Introduced with Capillary Tubes

{7}------------------------------------------------

5.6.3 Aqueous precision

Aqueous precision studies were performed in field trials by potential end users at two (2) hospitals on commercially available blood gas, electrolytes and metabolites control fluids, L1, L2 and L3 (Eurotrol, The Netherlands).

Site 1

User	QC Level	N	Avg	SD	%CV	lot
RN 1	L3	15	0.95	0.031	3.3%	09229
Anesthesia Tech	L3	15	0.94	0.027	2.9%	09229
RN 2	L2	14	2.88	0.05	1.8%	09229
Resp Therapist	L2	15	2.91	0.08	2.8%	09229

Figure 5.9 - Table - Aqueous Precision Study Summary (Site 1)

Site 2

------------------------------------------------------------------------------------------------------------iser	A STATE CONSULTION CONSULTION OF CONSULTION OF CONSULTION OF CONSULTION OF CONSULTION OF CONSULTION OF CONSULTION OF CONSULTION OF CONSULTION OF CONSULTION OF CONSULTION OF C	- Partificant Mitter ------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------		01 PM610 %ANNUAL AND AN AND CONSULER OF CONSULER OF CONSULERS OF CONSULERS OF CONSULERS OF CONSULERS OF CONSULERS OF CONSULERS OF CONSULERS OF CONSULERS OF CONSULERS OF CONSULERS OF CO	--------------------------------------
AND A BOOM A CALL ANDC	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	1	Property Autor		C1------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	വാറ്റംat and the lastA
A L & MINNE A----------------------1ﺮ			.	FRANCHILLAND AND AND AND1.	500I1 1 100	uanesسال الساب

Figure 5.10 - Table - Aqueous Precision Study Summary (Site 2)

Matrix Effects 5.6.4

	epoc Lactate vs. i-STAT
	venous	arterial	capillary	all
N	126	73	174	373
Sxx	0.113	0.116	0.290	0.215
Syy	0.586	0.455	0.517	0.530
intercept	0.211	-0.165	0.257	0.132
slope	0.937	1.032	0.955	0.967
Syx	0.750	0.831	1.062	0.948
X min	0.66	0.57	0.48	0.48
X max	19.88	19.95	19.57	19.95
R2	0.9769	0.9829	0.9653	0.9711

Figure 5.11 - Table of Method Comparison Summary Against Predicate Device By Sample Matrix Type

{8}------------------------------------------------

	Lactate, mM
matrix	Decision level	2.2	5.0
venous	Average Bias	0.073	-0.103
	95% Confidence Interval ±	0.165	0.113
arterial	Average Bias	-0.094	-0.004
	95% Confidence Interval ±	0.223	0.162
capillary	Average Bias	0.158	0.031
	95% Confidence Interval ±	0.198	0.142
all	Average Bias	0.061	-0.031
	95% Confidence Interval ±	0.119	0.084

Figure 5.12 - Table of Method Comparison Summary Against Predicate Device -Consolidated Bias by Sample Matrix Type

5.6.4.1 Effect of Anticoagulant

The effect of anticoagulant was evaluated on patient samples that were collected using heparinized and non-heparinized collection devices. This study was performed at various POC sites of a hospital (43 samples) and supplemented with in-house studies (17 samples). The data was analyzed using EP9-2A methodology.

epoc Lactate
No heparin vs. Heparinized
N	60
Sxx	0.091
Syy	0.160
intercept	-0.045
slope	1.036
Syx	0.232
X min	0.52
X max	11.21
R2	0.9916

Figure 5.13 - Table of Heparinized Versus Non-Heparinized Samples

Summary of Conclusions Drawn from Non Clinical and 5.7 Clinical Tests

We conclude from the data presented in section 5.5 that the device performs effectively. We conclude from the data section 5.6 that the clinical performance of the device is equivalent to the predicate device: i-Stat Model 300 Portable Clinical Analyzer.

{9}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Image /page/9/Picture/2 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three curved lines representing its wings and tail. The eagle is positioned to the right of a circular seal that contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter.

Epocal, Inc. c/o Mr. Roy Layer Director of Quality Assurance and Regulatory Affairs 2060 Walkley Road Ottawa, Ontario Canada K1G-3P5

Food & Drug Administration 10903 New Hampshire Avenue Building 66 Silver Spring, MD 20993

JUN 0 9 2000

Re: K093297

Trade Name: epoc Lactate test Regulation Number: 21 CFR §862.1450 Regulation Name: Lactic acid test system. Regulatory Class: Class I, meets limitations of exemptions, 21 CFR §862.9 (c)(9) Product Codes: KHP Dated: May 13, 2010 Received: May 17, 2010

Dear Mr. Layer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820).

{10}------------------------------------------------

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Courtney C. Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{11}------------------------------------------------

Indication for Use

k = 93297 510(k) Number (if known):

Device Name: epoc Lactate test

Indication For Use:

Prescription Use __ X (21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use _ (21 CFR Part 801 Subpart C) .

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Carol C. Benson

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) k 0 93217

Page 1 of 1

Regulation Number and Section

§ 862.1450 Lactic acid test system.

(a)
Identification. A lactic acid test system is a device intended to measure lactic acid in whole blood and plasma. Lactic acid measurements that evaluate the acid-base status are used in the diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood).(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.